Forbion's new €75M fund; Cara Therapeutics to cut workforce after trial failure
Plus, news about Cinclus Pharma, Biophytis and Blanver:
Forbion’s new fund: The Dutch VC firm’s BioEconomy Fund I closed €75 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.